December 2021 FDA Recall Drug by Remedyrepack Inc.
D-0366-2022 - CGMP Deviations
This Class II drug recall was voluntarily initiated by Remedyrepack Inc. on December 30, 2021 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in Product was distributed to one direct account in PA. and the recall is currently terminated.
Recall Number: D-0366-2022
CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
12-30-2021
01-19-2022
56 Blister Cards
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
RemedyRepack Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Product was distributed to one direct account in PA.
03-28-2022
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Metformin 750 mg Extended Release NDC # 70518-2920-00
Batch or Lot Expiration Information
Lot# J0511265-021121, exp. date 02/28/2022 J0499451-122220, exp. date 01/31/2022 J0496563-120820, exp. date 12/31/2021 J0495111-120120, exp. date 12/31/2021